Navigation Links
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
Date:9/29/2008

-- Company Also Announces Participation in Upcoming Investor Conferences in

October --

SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for October 2008, which includes six data presentations and one sponsored symposium at The Obesity Society Annual Scientific Meeting, as well as upcoming corporate presentations at noteworthy investor conferences.

The Obesity Society Annual Scientific Meeting, Phoenix Convention Center

Saturday, October 4

Poster Presentation

Abstract: 317-P

Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the

Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk

Subjects"

Time: 5:00-7:00 p.m. MT

Sunday, October 5

Symposium

Event Code: E1280

Title: "Reward and Obesity; Too Much of a Good Thing?"

Time: 6:15-7:45 a.m. MT

Location: Hyatt Regency Phoenix, Regency Ballroom A/B

Oral Presentation

Abstract: 61-OR

Presenter: Ronald Landbloom, M.D.

Title: "Long Term Weight Loss from a Dose Optimization Study with

Zonisamide SR and Bupropion SR"

Time: 11:00-11:15 a.m. MT

Poster Presentation

Abstract: 585-P

Title: "Relative Bioavailability of Sustained-release (SR) versus

Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese

Volunteers: Implications for Improved Tolerability?"

Time: 5:30-7:30 p.m. MT

Monday, October 6

Oral Presentation

Abstract: 104-OR

Presenter: Sonja K. Billes, Ph.D.

Title: "Leptin Regulates Food Intake Via Dopamine Receptor-Dependent

Mechanisms"

Time: 11:30-11:45 a.m. MT

Poster Presentation

Abstract: 847-P

Title: "Quality of Life Improvements from a Dose Optimization Study with

Zonisamide SR and Bupropion SR"

Time: 12:45-2:45 p.m. MT

Poster Presentation

Abstract: 848-P

Title: "Timing of Response from a Dose Optimization Study with Zonisamide

SR and Bupropion SR"

Time: 12:45-2:45 p.m. MT

Upcoming Corporate Presentations

JMP Securities Healthcare Sector Focus Conference

Le Parker Meridien, New York

October 6, 2008

10:00 a.m. ET

BIOCOM Investor Conference

Hyatt Regency La Jolla, San Diego

October 28, 2008

4:00 p.m. PT

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):